In-vitro and in-vivo activities of sulbactam and YTR830H against Acinetobacter calcoaceticus.
The antibacterial activities of sulbactam and YTR830H, both beta-lactamase inhibitors, were studied against Acinetobacter calcoaceticus, in vitro and in vivo. In-vitro susceptibility tests showed both to be very active against 80 clinical isolates of A. calcoaceticus. Against an intraperitioneal infection in mice, caused by A. calcoaceticus Ac54, the 50% effective doses of sulbactam and YTR830H were 1.62 and 16.7 mg/kg, respectively. Against A. calcoaceticus S31, a strain resistant to gentamicin, sulbactam and YTR830H were active both in vitro and in vivo.
Obana
Y
Y
Department of Microbiology, Kyoto Pharmaceutical University, Japan.
Nishino
T
T
D000150:Acinetobacter / Q000187:drug effects*; D000151:Acinetobacter Infections / Q000188:drug therapy / Q000382:microbiology; D000818:Animals; D006801:Humans; D008297:Male; D051379:Mice; D008826:Microbial Sensitivity Tests; D010397:Penicillanic Acid / Q000494:pharmacology* / Q000627:therapeutic use; D013407:Sulbactam / Q000494:pharmacology* / Q000627:therapeutic use; D000078142:Tazobactam; D065093:beta-Lactamase Inhibitors
D065093:beta-Lactamase Inhibitors; D010397:Penicillanic Acid; D013407:Sulbactam; D000078142:Tazobactam